Please wait while the formulary information is being retrieved.
Drug overview for METHENAMINE HIPPURATE (methenamine hippurate):
Generic name: METHENAMINE HIPPURATE (meth-EN-a-meen)
Drug class: Urinary Tract Anti-Infectives
Therapeutic class: Genitourinary Therapy
Methenamine is a synthetic urinary antibacterial agent that is chemically unrelated to other currently available anti-infectives.
No enhanced Uses information available for this drug.
Generic name: METHENAMINE HIPPURATE (meth-EN-a-meen)
Drug class: Urinary Tract Anti-Infectives
Therapeutic class: Genitourinary Therapy
Methenamine is a synthetic urinary antibacterial agent that is chemically unrelated to other currently available anti-infectives.
No enhanced Uses information available for this drug.
DRUG IMAGES
METHENAMINE HIPP 1 GM TABLET
The following indications for METHENAMINE HIPPURATE (methenamine hippurate) have been approved by the FDA:
Indications:
Prevention of bacterial urinary tract infection
Professional Synonyms:
Urinary tract infection prophylaxis
UTI prophylaxis
Indications:
Prevention of bacterial urinary tract infection
Professional Synonyms:
Urinary tract infection prophylaxis
UTI prophylaxis
The following dosing information is available for METHENAMINE HIPPURATE (methenamine hippurate):
Methenamine is commercially available as methenamine hippurate and methenamine mandelate; dosage is expressed in terms of the salt.
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| METHENAMINE HIPP 1 GM TABLET | Maintenance | Adults take 1 tablet (1 gram) by oral route 2 times per day |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| METHENAMINE HIPP 1 GM TABLET | Maintenance | Adults take 1 tablet (1 gram) by oral route 2 times per day |
The following drug interaction information is available for METHENAMINE HIPPURATE (methenamine hippurate):
There are 1 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Methenamine/Sulfonamides SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Methenamine is hydrolyzed to formaldehyde in acidic urine. Sulfonamides may form an insoluble precipitate with formaldehyde in the urine.(1,2) CLINICAL EFFECTS: The concurrent administration of methenamine and sulfamethizole or sulfathiazole is likely to form a precipitate in the urine.(1-3) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Methenamine should not be administered to patients receiving sulfonamides.(1-3) DISCUSSION: Methenamine is hydrolyzed to formaldehyde in acidic urine. An in vitro study showed that addition of methenamine and mandelic acid to saturated solutions of sulfamethizole at pH 5.0 and 6.0 produced a precipitate in one hour.(4) |
ACETAZOLAMIDE, ACETAZOLAMIDE ER, ACETAZOLAMIDE SODIUM, AZULFIDINE, BACTRIM, BACTRIM DS, DICHLORPHENAMIDE, KEVEYIS, METHAZOLAMIDE, ORMALVI, SULFACETAMIDE, SULFACETAMIDE SOD MONOHYDRATE, SULFACETAMIDE SODIUM, SULFADIAZINE, SULFADIAZINE SODIUM, SULFAMERAZINE, SULFAMETHOXAZOLE, SULFAMETHOXAZOLE-TRIMETHOPRIM, SULFANILAMIDE, SULFAPYRIDINE, SULFASALAZINE, SULFASALAZINE DR, SULFATHIAZOLE, SULFATRIM, SULFISOXAZOLE |
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| VOWST |
There are 0 moderate interactions.
The following contraindication information is available for METHENAMINE HIPPURATE (methenamine hippurate):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 3 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Kidney disease with reduction in glomerular filtration rate (GFr) |
| Severe dehydration |
| Severe hepatic disease |
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Disease of liver |
The following adverse reaction information is available for METHENAMINE HIPPURATE (methenamine hippurate):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 2 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Skin rash |
| Rare/Very Rare |
|---|
|
Hematuria |
There are 4 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Dyspepsia Nausea |
| Rare/Very Rare |
|---|
|
Dysuria Pruritus of skin |
The following precautions are available for METHENAMINE HIPPURATE (methenamine hippurate):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Reproduction studies in rats and rabbits using methenamine hippurate have not revealed evidence of harm to the fetus. A slight increase in the stillborn rate and slight impairment of weight gain and survival of live-born offspring was reported in a study in pregnant dogs using oral methenamine in dosages equivalent to the human dosage. There are no adequate and well-controlled studies to date using methenamine hippurate or methenamine mandelate in pregnant women, and the drugs should be used during pregnancy only when clearly needed.
Although safe use of methenamine or its salts during pregnancy has not been definitely established, the drugs have been used in pregnant women without adverse effects to the fetus. One manufacturer of methenamine hippurate states that safety during the last trimester is suggested, but not definitely proven. The effects of methenamine during labor and delivery are unknown and there are no recognized uses for the drug during labor or delivery.
Although safe use of methenamine or its salts during pregnancy has not been definitely established, the drugs have been used in pregnant women without adverse effects to the fetus. One manufacturer of methenamine hippurate states that safety during the last trimester is suggested, but not definitely proven. The effects of methenamine during labor and delivery are unknown and there are no recognized uses for the drug during labor or delivery.
Because methenamine is distributed into milk and because of the potential for serious adverse effects in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for METHENAMINE HIPPURATE (methenamine hippurate):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for METHENAMINE HIPPURATE (methenamine hippurate)'s list of indications:
| Prevention of bacterial urinary tract infection | |
| Z87.440 | Personal history of urinary (tract) infections |
Formulary Reference Tool